Back to top

vaccines: Archive

Zacks Equity Research

Pfizer (PFE) Posts Upbeat Data From Hemophilia Drug Study

Data from a late-stage study shows that treatment with Pfizer's (PFE) experimental anti-TFPI inhibitor led to a significant reduction in annualized bleeding rate in hemophilia A and B patients.

PFEPositive Net Change BMRNPositive Net Change NVOPositive Net Change QUREPositive Net Change

Zacks Equity Research

Valneva (VALN) Stock Down 53% in the Past Year: Here's Why

The European Commission's revised advance purchase agreement jeopardizes Valneva's (VALN) COVID-19 vaccine program.

AZNPositive Net Change PFEPositive Net Change ABUSPositive Net Change VALNPositive Net Change

Zacks Equity Research

EMA Panel Endorses Novavax's (NVAX) COVID Jab for Full Approval

Novavax's (NVAX) protein-based COVID-19 vaccine gets recommendation for full marketing authorization in COVID-19 patients from European Medicines Agency.

PFEPositive Net Change MRNAPositive Net Change NVAXPositive Net Change BNTXPositive Net Change

Zacks Equity Research

Icosavax (ICVX) Up on Positive VLP Vaccine Candidate Data

Icosavax (ICVX) surges on positive data from the clinical study of IVX-A12, targeting respiratory syncytial virus and human metapneumovirus in older adults.

ADMAPositive Net Change ALLOPositive Net Change

Zacks Equity Research

Moderna (MRNA) Posts Upbeat Data on Protein Replacement Therapy

Interim data from a study shows that Moderna's (MRNA) investigational therapy for propionic acidemia (PA) exhibited early signs of dose-dependent pharmacology and potential clinical benefits.

MRNAPositive Net Change ANIPNegative Net Change ALLOPositive Net Change LSTAPositive Net Change